stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Price to free cash flow
As of 5 November 2026, 10x Genomics (TXG) trades at a price to free cash flow of 82.7×. Over the past ten years it has ranged from 0.0× (March 2025) to 138× (October 2026); the current reading is higher than 98% of that period. That is above the Medical Devices industry median of 28.8× and above the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 15.8× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 127× | 207.90% |
| Jun 2026 | 41.4× | 84.11% |
| Mar 2026 | 22.5× | 42.63% |
| Dec 2025 | 15.8× | (13.37%) |
| 27 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 7.1× |
| GMED Globus Medical, Inc. compare | 14.5× |
| HAE Haemonetics Corporation compare | 18.1× |
| BIO Bio-Rad Laboratories, Inc. compare | 30.0× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 30.7× |
| BRKR Bruker Corporation compare | 32.9× |
| PODD Insulet Corporation compare | 46.4× |
| PEN Penumbra, Inc. compare | 63.1× |
| TXG 10x Genomics | 63.3× |
| Medical Devices industry median | 28.8× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement